Shattuck Labs, Inc.(STTK)
$7.90
Chart
Buy9 analysts
Target $14.00+77.2%

Key Metrics

TTM
Market Cap$713.94M
Revenue TTM$1.00M
Rev Growth FY26E-89.0%
Rev Growth YoY-66.6%
Price / Sales713.9x
Net Income TTM-$52.57M
Free Cash Flow-$41.24M
Gross Margin-750.9%
Operating Margin-5578.7%
Net Margin-5256.8%
Return on Equity-43.6%
Return on Assets-23.8%
Debt / Equity (MRQ)0.01
Current Ratio (MRQ)27.59
EPS TTM$-0.41
PRICE
Prev Close
8.06
Open
8.03
Day Range7.80 – 8.05
7.80
8.05
52W Range0.97 – 8.33
0.97
8.33
94% of range
50-Day MA
6.78(+16.5%)
200-Day MA
5.26(+50.2%)
VOLUME & SIZE
Avg Volume
1.3M
FUNDAMENTALS
P/E (TTM)
-15.5x
Not profitable
EPS (TTM)
Div Yield (TTM)
No dividend
Beta
1.19
Market-like
TECHNICAL
RSI (14)
61
Bullish momentum

Upcoming Events

EEarnings Report
In 75 days
Nov 10
DEx-Dividend
In 90 days
Nov 25
PDividend Pay
In 116 days
Dec 21

STTK News

About

Shattuck Labs, Inc. operates as a clinical-stage biotechnology company . The Company focuses on developing a novel class of biologic medicines for the treatment of cancer and autoimmune diseases. Shattuck Labs serves customers in the State of Texas.

Industry
Pharmaceutical Preparation Manufacturing
Casi DeYoungChief Business Officer
Arundathy Nirmalini PanditeChief Medical Officer
Andrew R. NeillChief Financial Officer
Suresh de SilvaChief Scientific Officer
Abhinav A. ShuklaChief Technical Officer
Brad HuckabeeVice President of Accounting & SEC reporting
Kelli CollinSenior Vice President of Quality
Thomas LampkinSenior Vice President of Regulatory Affairs
Stephen StoutGeneral Counsel, Corporate Secretary and Chief Ethics & Compliance Officer
Taylor H. SchreiberCo-Founder, Chief Executive Officer & Director
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.